Poland· PL-100403901
Lamzede
A velmanase alfa product containing velmanasum alfa, registered in Poland by Chiesi Farmaceutici S.p.A.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Velmanase alfa is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AB15 (velmanase alfa), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Velmanase alfa · ATC A16AB15
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Velmanasum alfa
- Manufacturer
- Chiesi Farmaceutici S.p.A.
- Country
- Poland (PL)
- ATC code
- A16AB15
- ATC class
- Velmanase alfa
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin08025153000761
- gtin08025153000754
- gtin08025153000747
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Velmanase alfa in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLAMZEDEChiesi Farmaceutici S.p.A., Parma
- SwitzerlandLamzede 10 mg, poudre pour solution pour perfusionChiesi SA
- FinlandLamzedeChiesi Farmaceutici S.p.A.
- United KingdomLamzede 10mg powder for solution for infusion vialsChiesi Ltd
- IrelandLamzede 10 mg powder for solution for infusionChiesi Farmaceutici S.p.A.
- IcelandLamzedeChiesi Farmaceutici S.p.A.*
- NorwayLamzedeChiesi Farmaceutici S.p.a.
- BelgiumLamzede 10 mgChiesi Farmaceutici
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lamzede
- Liechtenstein · Lamzede
- Norway · Lamzede
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f2eba39b-08c0-4e7c-9375-3c827095b64e GET /v1/drugs/f2eba39b-08c0-4e7c-9375-3c827095b64e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mg",
"packaging": "08025153000761 ¦ Rpz ¦ EU/1/17/1258/001 ¦ 127678\n1 fiol. 10 mg proszku\n08025153000754 ¦ Rpz ¦ EU/1/17/1258/002 ¦ 127679\n5 fiol. 10 mg proszku\n08025153000747 ¦ Rpz ¦ EU/1/17/1258/003 ¦ 127680\n10 fiol. 10 mg proszku",
"substance": "Velmanasum alfa 10 mg",
"common_name": "Velmanasum alfa",
"pl_product_id": "100403901",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about velmanase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.